Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, Status and Forecast 2020-2026
![](/report_cover/6975/global-alpha-1-antitrypsin-deficiency-augmentation-therapy-market-size-status-n-forecast-2020-2026_en.gif)
This report focuses on the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Alpha-1 Antitrypsin Deficiency Augmentation Therapy development in North America, Europe and Asia-Pacific.
The key players covered in this study
The key players covered in this study
- Grifols
- CSL
- Baxter
- Kamada
- Takeda
- Abeona
- Glassia
- Aralast NP
- Prolastin C
- Others
- Hospitals
- Specialty Clinics
- North America
- Europe
- Asia-Pacific
- To analyze global Alpha-1 Antitrypsin Deficiency Augmentation Therapy status, future forecast, growth opportunity, key market and key players.
- To present the Alpha-1 Antitrypsin Deficiency Augmentation Therapy development in North America, Europe and Asia-Pacific.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.
- To define, describe and forecast the market by type, market and key regions.
- History Year: 2015-2019
- Base Year: 2019
- Estimated Year: 2020
- Forecast Year 2020 to 2026
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue
1.4 Market Analysis by Type
1.4.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Glassia
1.4.3 Aralast NP
1.4.4 Prolastin C
1.4.5 Others
1.5 Market by Application
1.5.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Specialty Clinics
1.6 Coronavirus Disease 2019 (Covid-19): Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry Impact
1.6.1 How the Covid-19 is Affecting the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry
1.6.1.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Alpha-1 Antitrypsin Deficiency Augmentation Therapy Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Perspective (2015-2026)
2.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Trends by Regions
2.2.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Share by Regions (2015-2020)
2.2.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth Strategy
2.3.6 Primary Interviews with Key Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Market Size
3.1.1 Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Revenue (2015-2020)
3.1.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Players (2015-2020)
3.1.3 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Concentration Ratio
3.2.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in 2019
3.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players Head office and Area Served
3.4 Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Solution and Service
3.5 Date of Enter into Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Size by Type (2015-2020)
4.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Type (2021-2026)
5 ALPHA-1 ANTITRYPSIN DEFICIENCY AUGMENTATION THERAPY BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020)
5.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2015-2020)
6.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players in North America (2019-2020)
6.3 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020)
6.4 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2015-2020)
7.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players in Europe (2019-2020)
7.3 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020)
7.4 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020)
8 ASIA-PACIFIC
8.1 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2015-2020)
8.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players in Asia-Pacific (2019-2020)
8.3 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020)
8.4 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020)
(2015-2020)
(2015-2020)
9 KEY PLAYERS PROFILES
9.1 Grifols
9.1.1 Grifols Company Details
9.1.2 Grifols Business Overview and Its Total Revenue
9.1.3 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
9.1.4 Grifols Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020))
9.1.5 Grifols Recent Development
9.2 CSL
9.2.1 CSL Company Details
9.2.2 CSL Business Overview and Its Total Revenue
9.2.3 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
9.2.4 CSL Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
9.2.5 CSL Recent Development
9.3 Baxter
9.3.1 Baxter Company Details
9.3.2 Baxter Business Overview and Its Total Revenue
9.3.3 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
9.3.4 Baxter Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
9.3.5 Baxter Recent Development
9.4 Kamada
9.4.1 Kamada Company Details
9.4.2 Kamada Business Overview and Its Total Revenue
9.4.3 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
9.4.4 Kamada Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
9.4.5 Kamada Recent Development
9.5 Takeda
9.5.1 Takeda Company Details
9.5.2 Takeda Business Overview and Its Total Revenue
9.5.3 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
9.5.4 Takeda Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
9.5.5 Takeda Recent Development
9.6 Abeona
9.6.1 Abeona Company Details
9.6.2 Abeona Business Overview and Its Total Revenue
9.6.3 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
9.6.4 Abeona Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
9.6.5 Abeona Recent Development
10 ANALYST'S VIEWPOINTS/CONCLUSIONS
11 APPENDIX
11.1 Research Methodology
11.1.1 Methodology/Research Approach
11.1.2 Data Source
11.2 Disclaimer
11.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue
1.4 Market Analysis by Type
1.4.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Glassia
1.4.3 Aralast NP
1.4.4 Prolastin C
1.4.5 Others
1.5 Market by Application
1.5.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Specialty Clinics
1.6 Coronavirus Disease 2019 (Covid-19): Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry Impact
1.6.1 How the Covid-19 is Affecting the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry
1.6.1.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Alpha-1 Antitrypsin Deficiency Augmentation Therapy Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Perspective (2015-2026)
2.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Trends by Regions
2.2.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Share by Regions (2015-2020)
2.2.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth Strategy
2.3.6 Primary Interviews with Key Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Market Size
3.1.1 Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Revenue (2015-2020)
3.1.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Players (2015-2020)
3.1.3 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Concentration Ratio
3.2.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in 2019
3.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players Head office and Area Served
3.4 Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Solution and Service
3.5 Date of Enter into Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Size by Type (2015-2020)
4.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Type (2021-2026)
5 ALPHA-1 ANTITRYPSIN DEFICIENCY AUGMENTATION THERAPY BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020)
5.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2015-2020)
6.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players in North America (2019-2020)
6.3 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020)
6.4 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2015-2020)
7.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players in Europe (2019-2020)
7.3 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020)
7.4 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020)
8 ASIA-PACIFIC
8.1 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2015-2020)
8.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players in Asia-Pacific (2019-2020)
8.3 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020)
8.4 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020)
(2015-2020)
(2015-2020)
9 KEY PLAYERS PROFILES
9.1 Grifols
9.1.1 Grifols Company Details
9.1.2 Grifols Business Overview and Its Total Revenue
9.1.3 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
9.1.4 Grifols Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020))
9.1.5 Grifols Recent Development
9.2 CSL
9.2.1 CSL Company Details
9.2.2 CSL Business Overview and Its Total Revenue
9.2.3 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
9.2.4 CSL Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
9.2.5 CSL Recent Development
9.3 Baxter
9.3.1 Baxter Company Details
9.3.2 Baxter Business Overview and Its Total Revenue
9.3.3 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
9.3.4 Baxter Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
9.3.5 Baxter Recent Development
9.4 Kamada
9.4.1 Kamada Company Details
9.4.2 Kamada Business Overview and Its Total Revenue
9.4.3 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
9.4.4 Kamada Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
9.4.5 Kamada Recent Development
9.5 Takeda
9.5.1 Takeda Company Details
9.5.2 Takeda Business Overview and Its Total Revenue
9.5.3 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
9.5.4 Takeda Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
9.5.5 Takeda Recent Development
9.6 Abeona
9.6.1 Abeona Company Details
9.6.2 Abeona Business Overview and Its Total Revenue
9.6.3 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
9.6.4 Abeona Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
9.6.5 Abeona Recent Development
10 ANALYST'S VIEWPOINTS/CONCLUSIONS
11 APPENDIX
11.1 Research Methodology
11.1.1 Methodology/Research Approach
11.1.2 Data Source
11.2 Disclaimer
11.3 Author Details
LIST OF TABLES
Table 1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Market Segments
Table 2. Key Players Covered: Ranking by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue
Table 3. Ranking of Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Glassia
Table 6. Key Players of Aralast NP
Table 7. Key Players of Prolastin C
Table 8. Key Players of Others
Table 9. COVID-19 Impact Global Market: (Four Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players to Combat Covid-19 Impact
Table 14. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions (2015-2020)
Table 18. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth Strategy
Table 24. Main Points Interviewed from Key Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players
Table 25. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Players (2015-2020) (Million US$)
Table 26. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Players (2015-2020)
Table 27. Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy as of 2019)
Table 28. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Solution and Service
Table 31. Date of Enter into Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020) (Million US$)
Table 34. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Share by Type (2015-2020)
Table 35. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Type (2021-2026)
Table 36. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Share by Application (2015-2020)
Table 37. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020) (Million US$)
Table 38. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Share by Application (2021-2026)
Table 39. North America Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share (2019-2020)
Table 41. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020) (Million US$)
Table 42. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2015-2020)
Table 43. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020) (Million US$)
Table 44. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2015-2020)
Table 45. Europe Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share (2019-2020)
Table 47. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2015-2020)
Table 49. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2015-2020)
Table 51. Asia-Pacific Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (2019-2020) (Million US$)
Table 52. Asia-Pacific Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share (2019-2020)
Table 53. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020) (Million US$)
Table 54. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2015-2020)
Table 55. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020) (Million US$)
Table 56. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2015-2020)
Table 57. Grifols Company Details
Table 58. Grifols Business Overview
Table 59. Grifols Product
Table 60. Grifols Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 61. Grifols Recent Development
Table 62. CSL Company Details
Table 63. CSL Business Overview
Table 64. CSL Product
Table 65. CSL Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 66. CSL Recent Development
Table 67. Baxter Company Details
Table 68. Baxter Business Overview
Table 69. Baxter Product
Table 70. Baxter Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 71. Baxter Recent Development
Table 72. Kamada Company Details
Table 73. Kamada Business Overview
Table 74. Kamada Product
Table 75. Kamada Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 76. Kamada Recent Development
Table 77. Takeda Company Details
Table 78. Takeda Business Overview
Table 79. Takeda Product
Table 80. Takeda Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 81. Takeda Recent Development
Table 82. Abeona Company Details
Table 83. Abeona Business Overview
Table 84. Abeona Product
Table 85. Abeona Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 86. Abeona Recent Development
Table 87. Research Programs/Design for This Report
Table 88. Key Data Information from Secondary Sources
Table 89. Key Data Information from Primary Sources
Table 1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Market Segments
Table 2. Key Players Covered: Ranking by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue
Table 3. Ranking of Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Glassia
Table 6. Key Players of Aralast NP
Table 7. Key Players of Prolastin C
Table 8. Key Players of Others
Table 9. COVID-19 Impact Global Market: (Four Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players to Combat Covid-19 Impact
Table 14. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions (2015-2020)
Table 18. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth Strategy
Table 24. Main Points Interviewed from Key Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players
Table 25. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Players (2015-2020) (Million US$)
Table 26. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Players (2015-2020)
Table 27. Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy as of 2019)
Table 28. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Solution and Service
Table 31. Date of Enter into Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020) (Million US$)
Table 34. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Share by Type (2015-2020)
Table 35. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Type (2021-2026)
Table 36. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Share by Application (2015-2020)
Table 37. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020) (Million US$)
Table 38. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Share by Application (2021-2026)
Table 39. North America Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share (2019-2020)
Table 41. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020) (Million US$)
Table 42. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2015-2020)
Table 43. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020) (Million US$)
Table 44. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2015-2020)
Table 45. Europe Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share (2019-2020)
Table 47. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2015-2020)
Table 49. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2015-2020)
Table 51. Asia-Pacific Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (2019-2020) (Million US$)
Table 52. Asia-Pacific Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share (2019-2020)
Table 53. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020) (Million US$)
Table 54. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2015-2020)
Table 55. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020) (Million US$)
Table 56. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2015-2020)
Table 57. Grifols Company Details
Table 58. Grifols Business Overview
Table 59. Grifols Product
Table 60. Grifols Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 61. Grifols Recent Development
Table 62. CSL Company Details
Table 63. CSL Business Overview
Table 64. CSL Product
Table 65. CSL Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 66. CSL Recent Development
Table 67. Baxter Company Details
Table 68. Baxter Business Overview
Table 69. Baxter Product
Table 70. Baxter Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 71. Baxter Recent Development
Table 72. Kamada Company Details
Table 73. Kamada Business Overview
Table 74. Kamada Product
Table 75. Kamada Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 76. Kamada Recent Development
Table 77. Takeda Company Details
Table 78. Takeda Business Overview
Table 79. Takeda Product
Table 80. Takeda Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 81. Takeda Recent Development
Table 82. Abeona Company Details
Table 83. Abeona Business Overview
Table 84. Abeona Product
Table 85. Abeona Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 86. Abeona Recent Development
Table 87. Research Programs/Design for This Report
Table 88. Key Data Information from Secondary Sources
Table 89. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type: 2020 VS 2026
Figure 2. Glassia Features
Figure 3. Aralast NP Features
Figure 4. Prolastin C Features
Figure 5. Others Features
Figure 6. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Specialty Clinics Case Studies
Figure 9. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Report Years Considered
Figure 10. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions: 2020 VS 2026
Figure 12. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Players in 2019
Figure 15. Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in 2019
Figure 17. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Grifols Total Revenue (US$ Million): 2019 Compared with 2018
Figure 21. Grifols Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 22. CSL Total Revenue (US$ Million): 2019 Compared with 2018
Figure 23. CSL Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 24. Baxter Total Revenue (US$ Million): 2019 Compared with 2018
Figure 25. Baxter Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 26. Kamada Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Kamada Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 28. Takeda Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Takeda Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 30. Abeona Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Abeona Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 32. Bottom-up and Top-down Approaches for This Report
Figure 33. Data Triangulation
Figure 34. Key Executives Interviewed
Figure 1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type: 2020 VS 2026
Figure 2. Glassia Features
Figure 3. Aralast NP Features
Figure 4. Prolastin C Features
Figure 5. Others Features
Figure 6. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Specialty Clinics Case Studies
Figure 9. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Report Years Considered
Figure 10. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions: 2020 VS 2026
Figure 12. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Players in 2019
Figure 15. Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in 2019
Figure 17. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Grifols Total Revenue (US$ Million): 2019 Compared with 2018
Figure 21. Grifols Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 22. CSL Total Revenue (US$ Million): 2019 Compared with 2018
Figure 23. CSL Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 24. Baxter Total Revenue (US$ Million): 2019 Compared with 2018
Figure 25. Baxter Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 26. Kamada Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Kamada Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 28. Takeda Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Takeda Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 30. Abeona Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Abeona Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 32. Bottom-up and Top-down Approaches for This Report
Figure 33. Data Triangulation
Figure 34. Key Executives Interviewed